ctDNA

American Society of Clinical Oncology (ASCO) 2024 Annual Meeting is being held Friday, May 31st through Tuesday, June 4th, with numerous scheduled sessions related to minimal residual disease in colorectal cancer. Highlighted Sessions and Posters Use of MRD-Guided Strategies to Optimize Therapeutic Interventions Circulating Biomarkers: Who, What, Where, When, and Why? Gastrointestinal Cancer—Colorectal and Anal Abstracts and Posters Clinical validation of a novel circulating tumor DNA methylation assay for predicting recurrence of colorectal cancer in patients with curative-intent surgery by monitoring minimal residual disease. A phase II trial of TAS-102 in patients with colorectal cancer with ctDNA-defined [...]

Cancer Network posts 15-episode series "ASCO GI 2024: Updates in MRD Testing for the Management of Colorectal Cancer" in which medical oncologists highlight clinical trials presented at ASCO GI 2024 and discuss the utility of minimal residual disease (MRD) and circulating tumor DNA (ctDNA).

Cancer Network posts 10-episode series titled "Around the Practice: ctDNA in Treatment Decisions and Monitoring" in which expert oncologists discuss current and future use of minimal residual disease (MRD) and circulating tumor DNA (ctDNA) in colorectal cancer.